"Absolutely rush demand for the Russian vaccine"

The head of the Russian Direct Investment Fund, Kirill Dmitriev, said on the air of the Russia 1 TV channel that the Russian drug Sputnik V is in high demand all over the world.

“We see a really absolutely rush demand for the Russian vaccine all over the world, and this is due to the fact that it shows the best results both in terms of efficiency and in terms of safety,” TASS quoted Dmitriev as saying.

He stressed that the effectiveness of Sputnik V is confirmed not only by Russian data, but also by information from Mexico, Argentina, Hungary and many other countries.

Recall that Russia was the first in the world to register a coronavirus vaccine in August 2020.

According to the results of the analysis, the effectiveness of Sputnik V was 97.6% among Russians vaccinated with both components of the vaccine in the period from December 5, 2020 to March 31, 2021.

To date, the drug has been registered in more than 65 countries with a total population of over 3 billion people. 

Also on russian.rt.com "They are afraid of high consumer properties": Gunzburg explained why the EU is delaying the admission of "Sputnik V" to the market

"There was a splash after the May holidays"

Moscow Mayor Sergei Sobyanin said that the increase in detected cases of coronavirus infection COVID-19 after the May holidays in Moscow was associated with long weekends and the peculiarities of the spring epidemiological season.

“After the May holidays, there was just a surge in detections and hospitalizations, because many were at their dacha, at home for almost ten days and did not really want to go to polyclinics and hospitals.

And after waiting for the working days, they came with all this.

Therefore, we observed a certain surge, "Sobyanin said on the air of" Russia 1 ".

In addition, as the mayor of Moscow noted, in the fall and spring, there is traditionally an increase in any colds.

According to the headquarters, 9694 new cases of coronavirus were detected in Russia per day.

During this time, 7386 people fully recovered, 355 died from complications that developed against the background of COVID-19, and concomitant diseases.

In total, since the beginning of the pandemic, specialists in Russia have recorded 5,063,442 cases of coronavirus.

During the observation period, 121 162 deaths were recorded, 4 677 870 people recovered.

264,410 cases remain active.

According to Rospotrebnadzor, over the entire period, over 137.9 million tests were carried out for a new type of coronavirus infection, including 382 thousand in the last day.

527,541 people remain under medical supervision.

In Moscow, 3719 new cases of the disease were confirmed in 24 hours.

916 people were hospitalized, 59 died.

At the same time, 2,547 COVID-19 patients recovered.

  • RIA News

  • © Ilya Pitalev

Work on the Russian drug "MIR-19"

Earlier, the director of the Institute of Immunology of the FMBA of Russia, an immunologist, a corresponding member of the Russian Academy of Sciences Musa Khaitov, in an interview with RT, commented on reports that scientists from Australia and the United States announced the development of their own drug for coronavirus.

“This year we patented the world's first drug that has a specific etiotropic antiviral effect against the SARS-CoV-2 virus that causes COVID-19.

I must say that this drug is unique and it works on the basis of the RNA interference mechanism, ”he said.

According to Khaitov, Russian scientists were "very curious and pleased" to learn that "another very strong team - scientists from Australia and the United States - have developed a similar drug," which also acts on the basis of the RNA interference mechanism.

Also on russian.rt.com "Effectively" turns off "virus replication": FMBA received a patent for a drug for the prevention and treatment of COVID-19

At the same time, the scientist emphasized that the drugs under consideration have a significant difference.

In particular, the difference lies in the different target genes used in them and in the method of delivery.

“We have this inhalation introduction through a nebulizer directly into the upper and lower respiratory tract, where the virus directly replicates.

They have this intravenous delivery using liposomes, ”he said.

Khaitov also spoke about the publication of an article about MIR-19 in the leading scientific publication Allergy.



“We published our article, it was accepted for publication in a very serious scientific journal, the journal Allergy (this is the world's leading publication in the field of allergology and immunology) on March 15, 2021. And colleagues also published their very strong work in the same authoritative journal Molecular Therapy on May 5, 2021. That is, we are literally one and a half months ahead of our colleagues, ”he stressed.